<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Bradykinin (BK) liberates nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi>, prostacyclin, and tissue plasminogen activator from endothelial cells </plain></SENT>
<SENT sid="1" pm="."><plain>We hypothesized that BK B2 receptor knockout (KO) mice (BKB2R(-/-)) have increased <z:mp ids='MP_0005048'>thrombosis</z:mp> risk </plain></SENT>
<SENT sid="2" pm="."><plain>Paradoxically, the BKB2R(-/-) mice have long <z:mp ids='MP_0001914'>bleeding</z:mp> times and delayed carotid artery <z:mp ids='MP_0005048'>thrombosis</z:mp>, 78 +/- 6.7 minutes, versus 31 +/- 2.7 minutes in controls </plain></SENT>
<SENT sid="3" pm="."><plain>The mechanism(s) for <z:mp ids='MP_0005048'>thrombosis</z:mp> protection was sought </plain></SENT>
<SENT sid="4" pm="."><plain>In BKB2R(-/-) plasma coagulation, fibrinolysis and <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> proteins are <z:mpath ids='MPATH_458'>normal</z:mpath> except for an increased prekallikrein and decreased factor XI </plain></SENT>
<SENT sid="5" pm="."><plain>BKB2R(-/-) mice have elevated BK 1-5 (160 +/- 75 fmol/mL, vs 44 +/- 29 fmol/mL in controls) and <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi> (182 +/- 41 pg/mL, vs 49 +/- 7 pg/mL in controls) </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="8774">Ramipril</z:chebi> treatment shortens vessel occlusion time </plain></SENT>
<SENT sid="7" pm="."><plain>BKB2R(-/-) mice have elevated plasma 6-keto-<z:chebi fb="0" ids="28852">PGF1alpha</z:chebi> (666 +/- 232 ng/mL, vs 23 +/- 5.3 ng/mL in controls) and serum nitrate (61 +/- 5.3 microM, vs 24 +/- 1.8 microM in controls) </plain></SENT>
<SENT sid="8" pm="."><plain>Treatment with L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e> (NG-mono-<z:chebi fb="36" ids="29309">methyl</z:chebi>-<z:chebi fb="0" ids="16467,29952">L-arginine</z:chebi> <z:chebi fb="21" ids="35701">ester</z:chebi>) or <z:chebi fb="0" ids="44445">nimesulide</z:chebi> shortens the <z:mp ids='MP_0005048'>thrombosis</z:mp> time </plain></SENT>
<SENT sid="9" pm="."><plain>BKB2R(-/-) mice have increased angiotensin receptor 2 (AT2R) <z:chebi fb="2" ids="33699">mRNA</z:chebi> and protein expression </plain></SENT>
<SENT sid="10" pm="."><plain>Treatment with an AT2R <z:chebi fb="68" ids="48706">antagonist</z:chebi>, PD123 319, normalizes the <z:mp ids='MP_0005048'>thrombosis</z:mp> time and nitrate and 6-keto-<z:chebi fb="0" ids="28852">PGF1alpha</z:chebi> </plain></SENT>
<SENT sid="11" pm="."><plain>The long <z:mp ids='MP_0001914'>bleeding</z:mp> times in BKB2R(-/-) mice also correct with L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e> and <z:chebi fb="0" ids="44445">nimesulide</z:chebi> therapy </plain></SENT>
<SENT sid="12" pm="."><plain>In BKB2R(-/-) mice, <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi> binding to an overexpressed AT2R promotes thromboprotection by elevating nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> and prostacyclin </plain></SENT>
<SENT sid="13" pm="."><plain>These investigations indicate a pathway for <z:mp ids='MP_0005048'>thrombosis</z:mp> risk reduction via the plasma kallikrein/kinin and renin angiotensin systems </plain></SENT>
</text></document>